levofloxacin; imipenem/cilastitin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nosocomial Pneumonia
Conditions
Nosocomial Pneumonia
Trial Timeline
Dec 1, 1997 → Jun 1, 2001
NCT ID
NCT00236834About levofloxacin; imipenem/cilastitin
levofloxacin; imipenem/cilastitin is a phase 3 stage product being developed by Johnson & Johnson for Nosocomial Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT00236834. Target conditions include Nosocomial Pneumonia.
What happened to similar drugs?
0 of 3 similar drugs in Nosocomial Pneumonia were approved
Approved (0) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00236834 | Phase 3 | Completed |
Competing Products
7 competing products in Nosocomial Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ceftazidime-avibactam | AbbVie | Phase 1 | 21 |
| Ceftolozane/Tazobactam | Merck | Phase 1 | 29 |
| vancomycin monotherapy + daptomycin monotherapy | Novartis | Phase 3 | 32 |
| linezolid | Pfizer | Phase 3 | 40 |
| C Group + E Group | Pfizer | Phase 2/3 | 34 |
| ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator) | Pfizer | Phase 3 | 40 |
| Veronate | Bristol Myers Squibb | Pre-clinical | 26 |